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Abstract
Background and Aims: Celiac sprue is a life-long disease characterized by an intestinal inflammatory response to dietary
gluten. A gluten-free diet is an effective treatment for most patients, but accidental ingestion of gluten is common, leading
to incomplete recovery or relapse. Food-grade proteases capable of detoxifying moderate quantities of dietary gluten could
mitigate this problem.
Methods: We evaluated the gluten detoxification properties of two food-grade enzymes, aspergillopepsin (ASP) from
Aspergillus niger and dipeptidyl peptidase IV (DPPIV) from Aspergillus oryzae. The ability of each enzyme to hydrolyze gluten
was tested against synthetic gluten peptides, a recombinant gluten protein, and simulated gastric digests of whole gluten
and whole-wheat bread. Reaction products were analyzed by mass spectrometry, HPLC, ELISA with a monoclonal antibody
that recognizes an immunodominant gluten epitope, and a T cell proliferation assay.
Results: ASP markedly enhanced gluten digestion relative to pepsin, and cleaved recombinant a2-gliadin at multiple sites in
a non-specific manner. When used alone, neither ASP nor DPPIV efficiently cleaved synthetic immunotoxic gluten peptides.
This lack of specificity for gluten was especially evident in the presence of casein, a competing dietary protein. However,
supplementation of ASP with DPPIV enabled detoxification of moderate amounts of gluten in the presence of excess casein
and in whole-wheat bread. ASP was also effective at enhancing the gluten-detoxifying efficacy of cysteine endoprotease EP-
B2 under simulated gastric conditions.
Conclusions: Clinical studies are warranted to evaluate whether a fixed dose ratio combination of ASP and DPPIV can
provide near-term relief for celiac patients suffering from inadvertent gluten exposure. Due to its markedly greater
hydrolytic activity against gluten than endogenous pepsin, food-grade ASP may also augment the activity of therapeutically
relevant doses of glutenases such as EP-B2 and certain prolyl endopeptidases.
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Introduction
Celiac sprue is an inheritable, life-long disease that is
characterized by an inflammatory reaction to dietary gluten in
the human small intestine. The hallmark of the disease is a
characteristic flattening of intestinal villi along with crypt
hypertrophy. As a consequence, there is tremendous loss of
surface area and malabsorption of nutrients, vitamins and
minerals. If untreated, celiac sprue is associated with complications
such as anemia, bone diseases, infertility, neurological problems,
cancer and other complications due to persistent inflammation
and micronutrient deficiencies. Screening studies predict that
approximately 1% of the United States’ population has the
disease, yet only ca. 10% of affected individuals have been
diagnosed thus far [1]. At present, the only suitable treatment is
strict, life-long exclusion of gluten from the patient’s diet. Although
a large fraction of patients who attempt to follow such a diet still
exhibit signs or symptoms of active disease [2–5], there is no
available supplementary therapy for such conditions.
A potential cost-effective solution to the aforementioned problem
is an oral protease or protease mixture that is composed solely of
commercially available food-grade enzymes. In this study we have
evaluated the gluten detoxification properties of one such enzyme
cocktail. It includes at least two proteases, aspergillopepsin (ASP)
from Aspergillus niger and dipeptidyl peptidase IV (DPPIV) from
Aspergillus oryzae, both of which are widely used in the foods and
feeds, food processing and dietary supplement industries. Our data
suggest that, whereas neither enzyme preparation alone is able to
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ratio of the two enzyme preparations is able to detoxify moderate
quantities of dietary gluten. Clinical studies are therefore warranted
to evaluate the activity of this food-grade enzyme preparation in
celiac sprue patients with an inadequate response to a gluten-free
diet. Our results also show that, under gastric conditions, ASP
augments the efficacy of gluten-detoxifying endoproteases such as
the glutamine specific EP-B2 from barley [6].
Results
Identity
The Materials Safety Data Sheet of the commercial ASP powder
from Bio-Cat Inc. designates this enzyme as aspergillopepsin from
A. niger (EC 3.4.23.18). N-terminal sequencing of the major 41 kD
protein in this powder yielded an N-terminal sequence of –K-
SAVTT, consistent with its identity as aspergillopepsin A precursor
(a.k.a.,aspergillopepsinI)havinga molecularweightof41 kD.Mass
mapping of tryptic fragments further verified its identity. Pro-
aspergillopepsin A is believed to spontaneously self-activate into the
mature enzyme under acidic conditions [7].
The Materials Safety Data Sheet of the commercial Peptidase P
powder from Bio-Cat Inc. designates this enzyme as dipeptidyl
peptidase IV from A. oryzae (EC 3.4.21.63). Although DPPIV
activity could be verified by the chromogenic substrate Gly-Pro-
pNA, SDS-PAGE revealed that the enzyme preparation was a
complex mixture of proteins that lacked a prominent band with
MW higher than 75 kD, as might be expected for this DPPIV [8].
We therefore used an alternate strategy to verify the identity of this
serine protease in the commercial enzyme preparation. An
inhibition assay was performed with various concentrations of
known DPPIV inhibitor, Boc-L-Prolinal. At a concentration of
9 mM inhibitor in the reaction volume, 100% inhibition of DPPIV
(0.1 mg/ml) activity was observed.
Activity and stability of commercial ASP and DPPIV
preparations
The total protein content and specific activity of food-grade ASP
and DPPIV evaluated in this study is summarized in Table 1.
Periodicanalysisinourlaboratoriesdemonstrated that both enzyme
powders were stable for at least 6 months at room temperature.
Hydrolysis of gluten-derived proteins and peptides by
ASP and DPPIV
It is well established that mammalian pepsin exerts only minimal
proteolytic action on dietary gluten. Our search for food-grade gluten
detoxifying enzymes therefore led us to aspergillopepsin as a
potentially more potent analog of mammalian pepsin. We first
wished to investigate the specificity of ASP towards recombinant
gluten proteins and synthetic gluten peptides. Available literature
suggests that ASP cleaves proteins relatively non-specifically. For
example, ASP cleaves ribonuclease A at Tyr-X, Phe-X, His-X, Asn-
X, Asp-X, Gln-X and Glu-X bonds [9]. LC-MS analysis revealed
that ASP cleaved the peptide VQWPQQQPVPQPHQPF from c-
gliadin after Q5, P8 and V9 residues, and also cleaved the peptide
PFSQQQQPV from glutenin after Q4, Q5 and Q6 residues. In the
absence of other protein substrates, ASP cleaved the 33-residue
peptide LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF from
a2-gliadin (Figure 1A), as well as its truncated 28-residue derivative
PFPQPQLPYPQPQLPYPQPQLPYPQPQP (data not shown).
However, in the presence of the more complex substrate whole
gluten,ASPexhibitedminimalactivitytowardthe33-mer(Figure1B),
indicating that the enzyme has low specificity for this immunotoxic
epitope. Other immunotoxic gluten peptides, such as the 26-mer
FLQPQQPFPQQPQQPYPQQPQQPFPQ from c5-gliadin [10]
and the innate immune peptide LGQQQPFPPQQPYPQPQPF
[11], were similarly resistant to cleavage by ASP (data not shown).
Although ASP is not specific for immunotoxic gluten epitopes, it
may potentiate gluten detoxification by cleaving larger proteins into
short peptides that are accessible substrates for more specific
endopeptidases and exopeptidases [12,13]. To more thoroughly
investigate the potential of ASP for gluten detoxification, full-length
recombinant a2-gliadin protein was treated with ASP for 15 min
(substrate: enzyme ratio of 50:1, pH 4.5), and the resulting peptide
mixture was analyzed by LC-MS-MS. The data were searched
against the SwissProt database, from which a2-gliadin was correctly
identified as the best hit. Those peptides with ion scores .30 were
used to construct a cleavage map. Our analysis, summarized in
Table 1. Protein content and specific activity of aspergillopepsin
(ASP) and dipeptidyl peptidase IV (DPPIV) preparations used in
this study.
ASP DPPIV
Total protein (t=0) 1460.6% 1660.6%
Total protein (t=6 mo) 1360.4% 1560.7%
Specific activity (t=0) 15.260.2 units/mg2 . 3 60.1 units/g
Specific activity (t=6 mo) 13.460.4 units/mg2 . 7 60.1 units/g
Each measurement is an average of four enzyme samples, stored and analyzed
independently.
doi:10.1371/journal.pone.0006313.t001
Figure 1. Digestion of the proteolytically resistant 33-mer
peptide from a2-gliadin with aspergillopepsin (ASP). (A)
Reverse-phase HPLC traces of the 33-mer peptide incubated with ASP
in a 20:1 (w/w) peptide:enzyme ratio at pH 4.5. (B) Reverse-phase HPLC
traces of the 33-mer peptide mixed with gluten digested by pepsin, and
incubated with ASP in a 20:80:1 (w/w/w) peptide:gluten:enzyme ratio at
pH 4.5. The ordinate scale is identical in all traces. The peak at 15 min
corresponds to an internal standard (TAME).
doi:10.1371/journal.pone.0006313.g001
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sites, including H-X (X=S,A), Q-X (X=Q,V,S,E), R-X (X=V,N),
A-X (X=Y,P), K-Q, L-X (X=Q,V,P), F-X (X=P,E), P=X
(X=V,Q), T-X (X=I,N), Y-R, and S-X (X=F,Q) bonds.
Based on these findings with structurally defined substrates, we
hypothesized that, although ASP was considerably more effective
than mammalian pepsin at cleaving gluten into short peptides, it
would have limited ability to detoxify gluten in the context of a
complex meal. To test this hypothesis, we compared the activity of
pepsin versus ASP against 15 mg/ml whole gluten or 15 mg/ml
gluten mixed with 50 mg/ml casein under simulated gastric
conditions (0.03 M HCl). The markedly superior activity of ASP
against whole gluten is illustrated in Figure 3. However, as seen in
Figure 4, in the presence of a more abundant dietary protein such
as casein, ASP-catalyzed gluten detoxification is extremely
retarded. These results suggested that ASP mediated gluten
detoxification in the context of a complex meal would require a
second, complementary enzyme.
Preliminary studies with a variety of other over-the-counter
enzymes led us to conduct more detailed evaluations of peptidase P
from Aspergillus oryzae. This commercial enzyme preparation contains
the exopeptidase DPPIV, and is also widely used as a debittering
agent in foods and dietary supplements due to its specificity for
peptides with N-terminal X-P- sequences. Although the enzyme is
completely inactive against gluten at pH ,4, at higher pH values it
markedly enhances the extent to which ASP hydrolyzes gluten
(Figure 5). In earlier studies we observed that fungal DPPIV was
unable todetoxify immunotoxicgluten peptides whenaddedas a lone
supplement to gastrointestinal proteases [13]. We reconfirmed this
lack of utility of DPPIV as a single agent by incubating commercial
peptidase P with synthetic 33-mer from a2-gliadin or the 26-mer
from c5-gliadin or the innate immune peptide p31–49. In each case,
minimal-to-no peptide hydrolysis occurred, with the only new
products being slightly truncated analogs of the starting material
(data not shown). Thus, to the extent a glutenase cocktail could be
formulated by combining ASP and DPPIV, it would presumably
detoxify gluten in the stomach via the successive action of ASP on
intactglutenproteinsfollowed by DPPIV onthe peptidegeneratedby
ASP. This hypothesis was tested in a variety of simulated gastric
studies outlined below. Due to the pH constraints of DPPIV, this
enzyme cocktail required supplementation of the gastric digests with
antacid, a necessity likely to carry over to future studies in vivo.
Simulated gastric digestion of whole gluten and whole
wheat bread
WefirstwishedtoverifytheproteolyticactionofASPandDPPIV
on baked gluten in whole wheat bread. For this purpose digestions
and sample analyses were performed under simulated gastric
conditions developed earlierforbread [6]. Notably, attheend ofthe
gastricphaseofdigestion,sampleswereneutralizedandtreated with
trypsin and chymotrypsin to mimic the duodenal phase of protein
digestion. The reason for this additional step was to be able to
reliably compare the effect of ASP and DPPIV relative to pepsin
alone via reverse phase HPLC, as pepsin alone has negligible
proteolytic action on baked gluten [6]. As shown in Figure 6,
addition of ASP+DPPIV to pepsin leads to a marked enhancement
of gluten digestion under simulated gastric conditions.
To assess the dependence of gluten proteolysis on ASP and
DPPIV dose, we digested 50 mg/ml gluten in the presence of
0.03 M HCl and 3 mg/ml CaCO3 by varying the concentration
of one enzyme while keeping the other constant. Representative
data is shown in Figure 7. Whereas the activity of ASP on such a
high gluten concentration showed a relatively small increase in
activity over a 10-fold range of enzyme (Figure 7A), a progressive
increase in DPPIV activity is seen up to the highest achievable
concentration (0.7 mg/ml) of this enzyme preparation (Figure 7B).
Based on these studies, we estimated that ASP and DPPIV protein
concentrations of 0.35 mg/ml and 0.7 mg/ml would be practi-
cally achievable targets in the post-prandial stomach (correspond-
ing to oral doses of 250 mg ASP and 400 mg DPPIV).
Additionally, to assess the potential of the above ASP+DPPIV
cocktail for detoxifying gluten under conditions that more accurately
mimic the continuously changing environment of the post-prandial
stomach, gluten (alone or in combination with casein) was digested
with either pepsin or ASP+DPPIV. This experiment was started by
adding gluten (or gluten plus casein), an appropriate quantity of each
enzymeand3 mg/mlCaCO3to0.03 MHCltosimulate the entry of
Figure2.Proteolytic specificityofaspergillopepsin (ASP) for a2-gliadin. Thepurified,recombinantprotein substratewasincubated for15 min
with food-grade ASP in a 50:1 (w/w) substrate:enzyme ratio at pH 4.5. Cleavage sites were identified by LC/MS/MS, and are indicated by arrows.
doi:10.1371/journal.pone.0006313.g002
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PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6313Figure 3. Proteolysis of whole gluten by aspergillopepsin (ASP) under simulated gastric conditions. Whole gluten powder (15 mg/ml)
was incubated with either 0.35 mg/ml ASP, 0.6 mg/ml pepsin, or both enzymes at 37uC for 60 min at pH 2. The resulting product mixture was
analyzed by reverse-phase HPLC, as described in the text. The breakdown of longer gluten peptides into shorter ones is generally indicated by a
decrease in absorbance at higher retention times and a concomitant increase in absorbance at lower retention times. The peak at 15 min
corresponds to an internal standard (TAME).
doi:10.1371/journal.pone.0006313.g003
Figure 4. Detoxification of gluten by aspergillopepsin (ASP) under conditions simulating gastric digestion of a meal. (A) Whole gluten
powder (15 mg/ml) or (B) whole gluten powder (15 mg/ml) mixed with casein (50 mg/ml) was incubated with either 0.6 mg/ml pepsin or 0.35 mg/
ml ASP at 37uC for 15 or 60 min in 0.03 M HCl. Gliadin peptides present in the digests were analyzed by competitive ELISA using the G12 monoclonal
antibody, which is specific for the immunotoxic gliadin epitope QPQLPY.
doi:10.1371/journal.pone.0006313.g004
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this point the pH ofthe mixture was 3 (in the case of gluten alone) or 4
(in the case of gluten+casein). Every 5 min thereafter, an additional
0.01 M equivalent of concentrated HCl was added in order to
simulate the periodic squirting of acid into the fed stomach. After
1 hr, the pH was 1 (in the case of gluten alone) or 2.5 (in the case of
gluten+casein). At this time-point, samples were withdrawn from
each reaction mixture and analyzed via a competitive ELISA assay
that is specific for a representative immunotoxic epitope. Treatment
of gluten or gluten plus casein with ASP+DPPIV reduced the epitope
concentration by 7- or 4-fold, respectively, compared to the samples
treated with pepsin only (Figure 8).
Finally, to confirm that the reduction in QPQLPY epitope
measured by competitive ELISA (Figure 8) correlates with reduced
ability of the ASP/DPPIV digests to stimulate gluten-responsive T-
cell lines, gluten and casein digests were analyzed by both the G12
competitive ELISA and a standard T-cell proliferation assay. For this
comparison only the water-soluble fractions of the digests were
analyzed as the T-cell proliferation assay, although a more
pathogenically relevant measure of immunotoxicity, is not amenable
to measuring the latent immunotoxic gliadin epitopes of ethanol
extracts. The samples were therefore digested under simulated gastric
conditions as described for Figure 8, followed by trypsin and
chymotrypsin treatment for 30 min. This last step was added in order
to increasethe amount of gluten peptides present in the water-soluble
fraction, as pepsin has poor proteolytic activity on dietary gluten. As
shown in Figure 9, the combination of ASP and DPPIV was able to
reduce the amount of T-cell stimulatory peptides in the digests,
compared to the samples digested with pepsin, trypsin and
chymotrypsin. These results are consistent with the QPQLPY
concentration in the same digests measured by G12 competitive
ELISA, in which QPQLPY amount was 192.5612.4 mMi np e p s i n ,
trypsin and chymotrypsin digests, and 64.965.5 mM in the samples
where ASP and DPPIV were added.
Comparison with other glutenases
As discussed above, an attractive feature of aspergillopepsin is
that, unlike mammalian pepsin, aspergillopepsin is able to
extensively hydrolyze dietary gluten into short peptides. This
finding suggests that ASP should be able to complement the
glutenase activities of other promising enzymes such as the
glutamine-specific cysteine endoprotease EP-B2 from barley [14],
the proline-specific prolyl endopeptidase AN PEP from A. niger [15],
and the combination product composed of EP-B2 and prolyl
endopeptidase SC PEP from S. capsulata [6]. To test this hypothesis,
we assessed the proteolytic activity of the proenzyme form of EP-B2
inthepresenceorabsenceofASPona mixtureof glutenand casein.
Whereas EP-B2 is highly effective at cleaving the 33-mer peptide
from a2-gliadin, the toxic heptameric epitope QLPYPQP in wheat
bread digests is not hydrolyzed completely by EP-B2 alone [20]. As
seen in Figure 10, a combination of both EP-B2 and ASP led to a
further reduction in the concentration of the related epitope
QPQLPY than either enzyme alone. With respect to pepsin alone,
33-mer content in these digests measured by triple quadrupole LC-
MS was reduced 22% by ASP and was not detectable (correspond-
ing to $98% reduction) by EP-B2 or by EP-B2 plus ASP.
Figure 5. Effect of a food-grade dipeptidyl peptidase IV (DPPIV) preparation on gluten proteolysis by aspergillopepsin (ASP). Whole
gluten powder (50 mg/ml) was incubated for 60 min at 37uC with 0.35 mg/ml ASP in the presence or absence of 0.7 mg/ml DPPIV. Because this
enzyme preparation is inactive at pH ,4, the reaction was conducted in 0.03 M HCl in the presence of 1.5 mg/ml CaCO3 to simulate addition of a
standard over-the-counter antacid/calcium supplement. The pH of the resulting mixture varies between 4–5 for the duration of the reaction. The
peak at 15 min corresponds to an internal standard (TAME).
doi:10.1371/journal.pone.0006313.g005
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PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6313Figure 6. Effect of aspergillopepsin (ASP) and dipeptidyl peptidase IV (DPPIV) on the proteolysis of baked gluten in whole wheat
bread under simulated gastric and duodenal conditions. The reverse phase HPLC traces show the residual peptide content after whole wheat
bread was incubated with pepsin (0.6 mg/ml) under simulated gastric conditions, followed by trypsin (0.375 mg/ml) and chymotrypsin (0.375 mg/ml)
under simulated duodenal conditions (PTC) or PTC+ASP (0.35 mg/ml)+DPPIV (0.7 mg/ml). The peak at 15 min corresponds to an internal standard
(TAME). For experimental details, see text.
doi:10.1371/journal.pone.0006313.g006
Figure 7. Dose dependence of gluten proteolysis on aspergillopepsin (ASP) and dipeptidyl peptidase IV (DPPIV). Whole gluten powder
(50 mg/ml) was incubated for 60 min at 37uC with 0.7 mg/ml DPPIV and variable ASP concentration (A) or 0.35 mg/ml ASP and variable DPPIV concentration
(B). The reactions were conducted in 0.03 M HCl in the presence of 3 mg/ml CaCO3. The peak at 15 min corresponds to an internal standard (TAME).
doi:10.1371/journal.pone.0006313.g007
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PLoS ONE | www.plosone.org 6 July 2009 | Volume 4 | Issue 7 | e6313Figure 8. Gluten detoxifying activity of aspergillopepsin (ASP) and dipeptidyl peptidase IV (DPPIV) under conditions simulating
gastric digestion of a meal. (A) Whole gluten powder (15 mg/ml) or (B) whole gluten powder (15 mg/ml) mixed with casein (50 mg/ml) was
incubated with either 0.6 mg/ml pepsin or 0.35 mg/ml ASP and 0.7 mg/ml DPPIV at 37uC for 60 min. The digestions were initiated in 0.03 M HCl and
3 mg/ml CaCO3, and every 5 min additional HCl was added. Gliadin peptides present in the digests were analyzed by competitive ELISA using the
G12 monoclonal antibody, which is specific for the immunotoxic gliadin epitope QPQLPY.
doi:10.1371/journal.pone.0006313.g008
Figure 9. Stimulation of T-cell lines derived from biopsies of
celiac sprue patients with gluten digested by aspergillopepsin
(ASP) and dipeptidyl peptidase IV (DPPIV). Whole gluten powder
(15 mg/ml) mixed with casein (50 mg/ml) was incubated with either
0.6 mg/ml pepsin or 0.35 mg/ml ASP and 0.7 mg/ml DPPIV. The
digestions were initiated in 0.03 M HCl and 3 mg/ml CaCO3, and every
5 min additional HCl was added. After digestion for 60 min at 37uC, the
samples were further treated with 0.375 mg/ml trypsin and 0.375 mg/
ml chymotrypsin for 30 min at pH 6.0. The immunotoxic peptide
content in the water-soluble fraction of the digests was measured by a
T-cell proliferation assay. A stimulation index of 1 indicates background
levels of T-cell proliferation and is denoted with a horizontal line. The
name of the individual T-cell lines is indicated in the graph.
doi:10.1371/journal.pone.0006313.g009
Figure 10. Detoxification of gluten by aspergillopepsin (ASP)
and EP-B2 under conditions simulating digestion of a meal.
Whole gluten powder (15 mg/ml) and casein (50 mg/ml) were digested
with 0.6 mg/ml pepsin for 60 min at pH 4 (gastric conditions, GC),
followed by treatment with 0.375 mg/ml trypsin and 0.375 mg/ml
chymotrypsin for 30 min at pH 6.0 (duodenal conditions, DC). Where
indicated, 0.35 mg/ml ASP, and/or 0.375 mg/ml proEP-B2 were added
at the beginning of the gastric digestion phase. Gliadin peptides
present in the digests were analyzed by competitive ELISA using the
G12 monoclonal antibody, which is specific for the immunotoxic gliadin
epitope QPQLPY.
doi:10.1371/journal.pone.0006313.g010
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There is a cogent need for some form of near-term supportive
therapy for celiac sprue, because dietary gluten exclusion is often
less than complete. Patients on a restricted diet frequently suffer
nutrient and mineral malabsorption, resulting in deficiencies of iron
or calcium, and consequently in anemia and osteoporosis,
respectively. This has motivated us to evaluate commercially
available food-grade enzymes for their ability to detoxify low-to-
moderate doses of gluten. By way of calibration, one slice of wheat
bread contains ca. 3–4 g gluten, whereas the threshold of ‘‘safe’’
gluten for celiac patients is estimated to be in the 10–100 mg range
[16]. In most cases, inadvertent gluten exposure results from
consumption of 10–1000 mg of ‘‘invisible’’ gluten found in
commonplace food ingredients such as sauces, salad dressings, food
starches, thickeners malt extract and other flavoring agents, or
sometimes simply through cross-contamination during food prep-
aration. Therefore, we sought to devise an oral enzyme cocktail
based upon existing over-the-counter products that may be able to
detoxify up to 1 g gluten while the food is still in the stomach.
Aspergillopepsin, unlike mammalian pepsin, is able to extensively
hydrolyzedietary gluteninto shortpeptides. However, incontrast to
glutenases such as prolyl endopeptidases or barley EP-B2, which
have high specificity for immunotoxic Pro- and Gln-rich gluten
peptides such as the 33-mer from a2-gliadin, ASP lacks specificity
for these peptides. By virtue of its relatively low sequence specificity,
it can hydrolyze these peptides, but the presence of competing
substrates slows this hydrolysis considerably. The extensive
exoproteolytic action of a second enzyme such as the fungal DPPIV
accelerates clearance of short peptides, thereby facilitating the
access of longer gluten peptides to the ASP active site and their
eventual detoxification [13]. In short, our in vitro studies suggest that
detoxification of a low-dose of gluten can be achieved using ASP
and DPPIV. Since these enzymes have already been proven safe for
human consumption, this dual-therapy holds promise for the near-
term relief of the inflammatory intestinal response of celiac patients
who suffer from inadvertent gluten exposure. In addition, ASP may
be added to more potent and specific glutenases such as EP-B2 [6]
and certain microbial prolyl endopeptidases ([6,17]) to further
enhance their therapeutic potency. Controlled clinical studies of
these food-grade enzymes are therefore warranted.
Materials and Methods
Materials
Food-grade aspergillopepsin (ASP) from Aspergillus niger and
dipeptidyl peptidase IV (DPPIV) from Aspergillus oryzae enzymes
were supplied in powder form by Bio-Cat, Inc (Troy, VA). Whole
gluten was from Bob’s Red Mill (Milwaukie OR), and whole wheat
bread was from Alvarado St. Bakery (Rohnert Park, CA). Pepsin
was obtained from American Laboratories (Omaha, NE). Trypsin
(from bovine pancreas, T4665), a-chymotrypsin (type II from
bovine pancreas, C4129), bovine hemoglobin (H-2625) and casein
(from bovine milk, C7078) were from Sigma (St. Louis, MO). The
substrate for assaying DPPIV activity (Gly-Pro-p-nitroanilide) was
from Bachem (Torrance, CA).
Protein and peptide production
Gluten peptides were synthesized on solid-phase using Boc/
HBTU chemistry, purified by reverse phase HPLC, and lyophilized
as described [18]. Peptides were resuspended in 50 mM sodium
phosphate, pH 7.0+0.02% NaN3 prior to use. Recombinant a2-
gliadin was expressed heterologously in E. coli and purified as
described [19].
Identity
The identity of aspergillopepsin was confirmed via N-terminal
sequence analysis and mass spectrometry of a trypsin digest of the
major protein observed at 41 kD by SDS-PAGE. Due to its low
abundance in the commercial enzyme powder from A. oryzae,t h e
identityofthe DPPIV proteincouldnotbe unequivocallyestablished
by protein sequencing. However, to confirm the presence of DPPIV
in this powder, we performed two assays. First, a standard
chromogenic assay for DPPIV was performed using Gly-Pro-p-
nitroanilide as a substrate. Second, an inhibition assay was
performed with a known DPPIV inhibitor, Boc-L-Prolinal.
Specificity
The specificity of ASP was assessed by LC/MS/MS analysis of
a2-gliadin digested with the commercial enzyme powder from A.
niger, as previously described [14]. In brief, digestions were
performed at a substrate: enzyme ratio of 50:1 at pH 4.5 for 15
minutes. Additional analysis was conducted with the following
immunogenic peptides: LQLQPFPQPQLPYPQPQLPYPQPQL-
PYPQPQPF and its truncated analog PFPQPQLPYPQPQL-
PYPQPQLPYPQPQP, and the innate immune peptide LGQ-
QQPFPPQQPYPQPQPF from a-gliadin; two c-gliadin peptides,
FLQPQQPFPQQPQQPYPQQPQQPFPQ and VQWPQQQP-
VPQPHQPF; and a glutenin peptide PFSQQQQPV.
Assays to measure enzyme specific activity
The protein concentration in each commercial enzyme prepa-
ration was determined by the Bradford protein assay. A standard
calibration curve was generated using bovine serum albumin in the
concentration range of 2–12 mg/ml.
ASP activity was measured using the spectrophotometric
hemoglobin units of tyrosine (HUT) assay. The amount of tyrosine
liberated as trichloroacetic acid-soluble peptides upon hemoglobin
digestion was quantified by monitoring absorbance at 280 nm. In a
total reaction volume of 1.5 ml, 1.3% (w/v) of bovine hemoglobin
was reacted at 37uC with three separate enzyme concentrations
(finalconcentrationsof 1.7 mg/ml, 5 mg/ml, and 8 mg/ml on a total
protein basis). After 10 min, the reaction was quenched using
trichloroacetic acid (TCA, Sigma 490–10) added to a final
concentration of 3.2% (w/v). Samples were centrifuged and the
A280 was recorded. One HUT unit of protease activity is defined as
that amount of enzyme that produces an A280 of 0.001 per min at
pH 2.0 and 37uC, measured as TCA-soluble products using
hemoglobin as a substrate (final volume=4 ml, light path=1 cm).
DPPIV activity was measured via a standard kinetic assay, using
the chromogenic substrate Gly-Pro-p-nitroanilide dissolved in
phosphate buffered saline, pH 7.4. Absorbance was monitored at
410 nm. One unit of DPPIV activity is defined as the amount of
enzyme that produces 1 mmol of p-nitroaniline per min at pH 4.5
and room temperature.
Simulated gastric and duodenal digestion of gluten
To evaluate the gluten detoxifying activity of a given enzyme or
enzyme cocktail, an experimental protocol developed earlier was
used to mimic the gastric digestion of either whole gluten or whole
wheat bread in vitro [6].
To simulate duodenal digestion, we adjusted the pH to 6.0 at
the end of the gastric phase. Pancreatic enzymes (trypsin and
chymotrypsin) were added to yield final concentrations of
0.375 mg/ml each. Addition of elastase and carboxypeptidase A
have minimal incremental effect on gluten digestion and thus were
not added [6,20]. The solution was then incubated at 37uC for up
to 30 min. Samples were taken at various time-points and heat-
treated as previously described.
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Chromotography (HPLC)
Digested gluten or bread samples were centrifuged for 10 min at
13,400Ng and filtered through a 0.2 mm low protein binding filter.
The filtrate was chromatographically separated on a 4.66150 mm
reverse phase C18 protein and peptide column (Vydac, Hesperia,
CA) using Dynamax SD-200 pumps (Varian, Palo Alto, CA)
(1 ml/min), a Varian 340 UV detector set at 215 nm and a
Varian Prostar 430 autosampler. Solvent A was water with 5.0%
acetonitrile and 0.1% TFA. Solvent B was acetonitrile with 5.0%
water and 0.1% TFA. Samples were analyzed using a gradient
described previously [6].
Competitive ELISA for immunotoxic gliadin epitopes
Relative amounts of immunotoxic gliadin epitopes in any gluten-
containing sample were quantified by a competitive enzyme-linked
immunoabsorbent assay (ELISA) using the horseradish peroxidase-
conjugated G12 monoclonal antibody (Biomedal, Seville, Spain)
[21] that is specific for the hexapeptide QPQLPY from the 33-mer
peptide of a2-gliadin [19]. Residual gliadin peptides in a given
sample were recovered by fully dissolving in 60% ethanol at room
temperature. On day 1 of the ELISA procedure, the Maxisorp
plates (Nalge Nunc, Rochester, NY) were coated with 100 ml/well
of a standard gliadin solution (Sigma) (5 mg/ml, diluted in 20 mM
phosphate buffer) and 100 ml of 0.02 M sodium carbonate buffer
(pH 9.6), and incubated 1 h at 37uC and overnight at 4uC. On day
2,100 mlofdifferentdilutions(1:500 to1:160,000)ofeach sampleas
well as standard solutions of the synthetic 33-mer peptide (0–10 mg/
ml) were incubated for 2 hr at room temperature with 100 ml G12-
HRP antibody solution (diluted 1:10,000 in PBS containing 3%
bovineserumalbumin).Thegliadin-coated plateswerethenwashed
twice with washing buffer (PBS containing 0.05% Tween-20,
300 ml/well), and blocked with blocking solution (washing buffer
plus 5% powder milk, 300 ml/well). Antibody and antigen
(standards or samples) mixes were added to the wells in duplicate
(200 ml/well) and incubated for 30 min at room temperature. Plates
were washed five times and exposed to 100 ml per well of HRP
substrate (Sigma, St. Louis, MO). After incubation for 30 min at
room temperature, color development was stopped with 1 M
sulfuric acid (100 ml per well) and the absorbance was measured at
450 nm. The concentration of the QPQLPY epitope was
determined using Sigma Plot 9.0 (Systat Software, Point Richmond,
CA) and a 4-parameters model. Each sample was analyzed in
duplicate.
3Q LC-MS/MS analysis of 33-mer
The content of 33-mer peptide present in gluten digests was
determined by triple quadrupole LC-MS. Whole gluten (15 mg/
ml) and casein (50 mg/ml) were digested with pepsin for 60 min at
pH 4.0 followed by treatment with 0.375 mg/ml trypsin and
0.375 mg/ml chymotrypsin for 30 min at pH 6.0. In designated
digests, pepsin was supplemented with 0.35 mg/ml ASP and/or
0.375 mg/ml EP-B2. Heat-quenched digests were centrifuged
(16,100 x g) and the supernatants were diluted in an equal volume
of cold acetonitrile containing 0.1% formic acid to precipitate
larger proteins. Samples were vortexed, incubated for 2 h at 4uC,
and centrifuged (16,100 x g) for 10 min at 4uC. Supernatants were
mixed with an equal volume of 0.1% formic acid in water to dilute
the acetonitrile concentration to 25%, and injected on a
Micromass Quattro Premier triple quadrupole LC-MS system.
The concentration in each sample was determined by comparison
to a 33-mer standard curve. The limit of quantification was 2 nM.
Gluten Deamidation
Digests were treated with 100 mg/ml recombinant human
transglutaminase 2 in 200 mM MOPS, pH 7.2, and 15 mM
CaCl2 for 2 h at 37uC. The samples were heated at .95uC for at
least 5 min to inactivate the enzyme, centrifuged for 2 min at
13,000 rpm to pellet insoluble material, and frozen at 220uC until
use in T cell proliferation assays.
T-Cell Lines and
3H Thymidine T-Cell Proliferation Assay
T-cellproliferationassayswereperformedusingDQ2homozygous
9088 cells and T-cell lines P28 TCL1 and P34 TCL1 as described in
Siegel et al. ([22]) except 1 mCi/well of [methyl-
3H]-thymidine was
pulsed for 15 h before harvesting the cells. Samples were diluted to
protein concentrations ranging from 0.001 to 1 mg/ml. Samples
were analyzed in duplicate. Stimulation index was determined as the
radioactive counts per minute (CPM) in the presence of the peptide
divided by the CPM in the absence of the peptide.
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